PerkinElmer Prices Offering of Senior Notes
March 04 2021 - 6:24PM
Business Wire
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to
innovating for a healthier world, announced today that it has
priced an offering of $400.0 million aggregate principal amount of
2.550% Senior Notes due 2031 at an issue price of 99.965% of the
principal amount and $400.0 million aggregate principal amount of
3.625% Senior Notes due 2051 at an issue price of 99.999% of the
principal amount.
The issuance of the notes is expected to close on March 8, 2021,
subject to customary closing conditions. The notes will pay
interest on a semi-annual basis.
PerkinElmer plans to use approximately $561 million of the net
proceeds of the offering to repay amounts borrowed under its senior
unsecured revolving credit facility to fund a portion of the
purchase price for its acquisition of Oxford Immunotec Global PLC.
PerkinElmer expects to use the remaining net proceeds of the
offering to repay at maturity a portion of its outstanding €300.0
million aggregate principal amount of 0.600% senior notes due
2021.
The joint book-running managers for the offering are J.P. Morgan
Securities LLC, BofA Securities, Inc., and Wells Fargo Securities,
LLC.
The offering is being made pursuant to an effective registration
statement on Form S-3 (including a prospectus) filed with the U.S.
Securities and Exchange Commission (“SEC”). Prospective investors
should read the prospectus forming a part of that registration
statement and the prospectus supplement related to the offering and
the other documents that PerkinElmer has filed with the SEC for
more complete information about the company and this offering.
These documents are available at no charge by visiting EDGAR on the
SEC website at www.sec.gov. Alternatively, copies of the prospectus
supplement and the accompanying prospectus relating to the offering
can be obtained by calling one of the joint book-running managers
at the following: J.P. Morgan Securities LLC collect at
1-212-834-4533 or BofA Securities, Inc. toll-free at
1-800-294-1322.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
About PerkinElmer
PerkinElmer, Inc. is a global leader focused on innovating for a
healthier world. The Company reported revenue of approximately $3.8
billion in 2020, has about 14,000 employees serving customers in
more than 190 countries, and is a component of the S&P 500
Index.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about PerkinElmer’s
intended use of proceeds, including its acquisition of Oxford
Immunotec Global PLC. These statements involve a number of risks
and uncertainties that could cause actual results to differ
materially from currently anticipated results, including risks and
uncertainties relating to capital markets conditions and completion
of the offering. Additional important factors and information
regarding PerkinElmer’s business that could cause actual results to
differ materially from those indicated by such forward-looking
statements are set forth in the prospectus and preliminary
prospectus supplement dated March 4, 2021 related to the offering,
which is on file with the SEC and available in the “Investors”
section of the Company’s website under the heading “SEC Filings,”
and the documents incorporated by reference into the prospectus and
prospectus supplement. While PerkinElmer may elect to update
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so, even if
circumstances change and, therefore, you should not rely on these
forward-looking statements as representing the Company’s views as
of any date subsequent to today.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210304006173/en/
Investor Relations: PerkinElmer, Inc. Bryan Kipp, 781-663-5583
bryan.kipp@perkinelmer.com
Media Relations: PerkinElmer, Inc. Chet Murray, 781-462-5126
chet.murray@perkinelmer.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Apr 2024 to May 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From May 2023 to May 2024